Qualigen Therapeutics Inc
For the period ended Dec 31, 2023. Filed Apr 8, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Apr 8, 2024
FFR$0.89-1.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY
| Common Stock · Additional · Accumulated Other Comprehensive · Total Qualigen Therapeutics, Inc. Stockholders’ · Total Stockholders’ | ||||||||
|---|---|---|---|---|---|---|---|---|
| Shares | Amount | Paid-In Capital | Income (Deficit) | Accumulated Deficit | Equity (Deficit) | Noncontrolling Interest | Equity (Deficit) | |
| Balance at December 31, 2022 | 4,210,737 | $42,110 | $110,528,050 | $50,721 | $(103,385,172) | $7,235,709 | $1,530,881 | $8,766,590 |
| Voluntary conversion of convertible debt into common stock | 841,726 | 842 | 1,111,740 | — | — | 1,112,582 | — | 1,112,582 |
| Redemptions of convertible debt into common stock | 309,665 | 310 | 254,006 | — | — | 254,316 | — | 254,316 |
| Fair value of warrant modification for professional services | — | — | 7,945 | — | — | 7,945 | — | 7,945 |
| Fair value of warrant reclassified from liabilities to equity | — | — | 1,626,694 | — | — | 1,626,694 | — | 1,626,694 |
| Stock-based compensation | — | — | 1,098,533 | — | — | 1,098,533 | 9,297 | 1,107,830 |
| Foreign currency translation adjustment | — | — | 28,597 | 81,170 | — | 109,767 | 38,303 | 148,070 |
| Deconsolidation of discontinued operations | — | — | — | (131,891) | — | (131,891) | (1,235,443) | (1,367,334) |
| Net loss | — | — | — | — | (13,417,212) | (13,417,212) | (343,038) | (13,760,250) |
| Balance at December 31, 2023 | 5,362,128 | $43,262 | $114,655,565 | $— | $(116,802,384) | $(2,103,557) | $— | $(2,103,557) |
| Common Stock · Additional · Accumulated Other · Total Qualigen Therapeutics, Inc. · Total | ||||||||
|---|---|---|---|---|---|---|---|---|
| Shares | Amount | Paid-In Capital | Comprehensive Income | Accumulated Deficit | Stockholders’ Equity | Noncontrolling Interest | Stockholders’ Equity | |
| Balance at December 31, 2021 | 3,529,018 | $35,290 | $101,274,073 | $— | $(84,744,629) | $16,564,734 | $— | $16,564,734 |
| Stock issued upon exercise of warrants | 332,000 | 3,320 | 4,711 | — | — | 8,031 | — | 8,031 |
| Stock-based compensation | — | — | 5,484,044 | — | — | 5,484,044 | — | 5,484,044 |
| Common stock and prefunded warrants issued for business acquisition | 350,000 | 3,500 | 3,740,417 | — | — | 3,743,917 | 3,882,225 | 7,626,142 |
| Noncontrolling interest adjustments relating to Stock-based compensation and other | — | — | (42,756) | — | — | (42,756) | 42,756 | — |
| Foreign currency translation adjustment | — | — | — | 50,721 | — | 50,721 | — | 50,721 |
| Fair value of warrant modification for professional services | — | — | 67,370 | — | — | 67,370 | — | 67,370 |
| Fair value of warrant modification for business acquisition | — | — | 696 | — | — | 696 | — | 696 |
| Issuance of rounded shares as a result of the reverse stock split | (281) | — | (505) | — | — | (505) | — | (505) |
| Net loss | — | — | — | — | (18,640,543) | (18,640,543) | (2,394,100) | (21,034,643) |
| Balance at December 31, 2022 | 4,210,737 | $42,110 | $110,528,050 | $50,721 | $(103,385,172) | $7,235,709 | $1,530,881 | $8,766,590 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.